ABBV - Myovant Squares Off with AbbVie On Endometriosis Treatment
Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. The study evaluating relugolix as a treatment for pain caused by endometriosis met two co-primary endpoints and a slate of secondary endpoints. Relugolix has clearly pointed its crosshairs on AbbVie's Orilissa, approved by the Food and Drug Administration (FDA) in 2018.
The painful condition of endometriosis is caused when tissue similar to the lining of the uterus grows outside of the uterus, according to the Mayo Clinic. The pain, which can be severe, is often exacerbated during the menstrual cycle. Endometriosis can also lead to fertility problems. The Endometriosis Foundation of America says up to 10 million women in the U.S. and 200 million worldwide live with endometriosis.
Image Source: Getty Images